Elumn8 Medical - Image-Guided Coronary Intervention Pioneer

admin52026-04-16 23:50:32

📢 Important Milestone (February 2026):
Elumn8 Medical (formerly Simpson Interventions) completed its Series C financing raising $17.5 million and officially rebranded to Elumn8 Medical, reflecting the company's evolution toward image-enabled coronary interventions. The name "Elumn8" references this being the eighth medical device company founded by Dr. John B. Simpson.

Company Overview (Updated April 2026)

Elumn8 Medical is a privately held medical technology company headquartered in Campbell, California. Founded in 2019 as Simpson Interventions, the company rebranded to Elumn8 Medical in February 2026. The company specializes in developing advanced image-guided catheter systems for treating coronary chronic total occlusions (CTOs), one of the most persistent challenges in interventional cardiology.

Mission: To transform the treatment of coronary chronic total occlusions by integrating real-time intravascular imaging with controlled guidewire crossing and re-entry capabilities, improving procedural efficiency, predictability, and safety for patients with complex coronary artery disease.

Corporate Evolution and Rebranding (2026)

Series C Financing and Rebrand (February 18, 2026)

Financing Details:

- Amount Raised: $17.5 million in Series C financing

- Purpose: Support continued clinical development of the Acolyte Image-Guided Crossing and Re-Entry Catheter System

- Significance: Initial close of Series C marks a pivotal milestone in the company's growth trajectory

Rebranding Rationale:

The transition from Simpson Interventions to Elumn8 Medical reflects:

- Strategic Evolution: Expanded focus on image-enabled technologies for coronary interventions

- Founder Legacy: Recognition of Dr. John B. Simpson's eighth medical device company founding (hence "Elumn8")

- Market Positioning: Better alignment with the company's mission to visualize complex coronary anatomy

Core Product: Acolyte Image-Guided Crossing and Re-Entry System

Technology Overview

The Acolyte™ System is the first combination imaging and crossing device designed specifically for treating coronary chronic total occlusions. It integrates:

- Optical Coherence Tomography (OCT): Provides real-time intravascular imaging directly within the catheter

- Crossing & Re-entry Capabilities: Integrated guidewire LaunchPad aids with vessel re-entry when necessary

- Concurrent Visualization: Enables wire delivery during simultaneous fluoroscopy and OCT imaging

Clinical Application

Target Condition: Coronary Chronic Total Occlusions (CTOs)

- Prevalence: Over 250,000 CTOs diagnosed annually in the US by coronary angiogram

- Patient Impact: Over 1.8 million US patients live with persistent chest pain, decreased quality of life, and reduced exercise capacity due to untreated CTOs

Clinical Advantages:

- Supports controlled guidewire true-lumen crossing

- Enables targeted re-entry into the correct blood flow channel distal to the lesion

- Improves procedural predictability and safety in complex CTO-PCI procedures

Regulatory Status

- FDA Breakthrough Device Designation: Granted in April 2024

- FDA TAP Program: Accepted into FDA's Total Product Life Cycle Advisory Program (TAP) in May 2024

- IDE Approval: Investigational Device Exemption approved by FDA in January 2025

- Clinical Trial Status: Currently enrolling patients in the Acolyte-PCI pre-market clinical trial (NCT06795763), with up to 103 patients across approximately 15 US centers

- First Patient Treated: August 2025 at Emory University Hospital

- Study Completion: Estimated September 2026

NOTE: The Acolyte System remains investigational and is limited by United States law to investigational use. Not available for sale in any geography.

Leadership Team

Executive Leadership

Chief Executive Officer: Joe Knight, PhD, MBA

- Appointed June 2024

- Previously served in leadership roles at multiple cardiovascular device companies

Founder, Chairman & Chief Medical Officer: John B. Simpson, PhD, MD

- Founder of eight medical device companies (hence "Elumn8")

- Seminal advancements in coronary and peripheral interventions have transformed interventional cardiology

- Remains actively involved as Chairman and CMO

Co-founder and Chief Technology Officer: Kin F. Chan, PhD

Vice President, Research & Development: Douglas Rowe

Clinical Advisory Board

- Tomoaki Hinohara, MD

- Bill Lombardi, MD

- David Kandzari, MD

- Bill Nicholson, MD

- Greg Robertson, MD

Market Opportunity and Clinical Challenge

The CTO Treatment Gap

Chronic total occlusions represent one of the most persistent challenges in interventional cardiology:

- Current Treatment Disparity: CTO-PCI is performed only in a minority of eligible patients due to lack of reliable, effective tools

- Surgical Alternative: CABG (coronary artery bypass graft) open-heart surgery is performed approximately 10x more frequently than CTO-PCI in the US, despite being highly invasive and costly

- Medical Management: 1.8 million patients in the US receive only medical management for CTO-related angina, with 80% reporting significant angina despite therapy